A Phase 2b, Randomized, Double-blind Study of Redasemtide (S-005151) in Adult Participants With Acute Ischemic Stroke
← catalyst calendarSponsored by Shionogi (industry) · 4507.T — their whole pipeline →.
Phase
Phase 2
Status
Completed
Study type
Interventional
Design
Randomized · Double · Treatment
Enrollment
680actual
Sites
150
Countries
Australia, Belgium, China +14
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2023-07-14 | actual | When the study began enrolling |
| Primary completion | 2026-06-15 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-06-15 | actual | The whole study's end, after follow-up |
| First posted | 2023-07-20 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-30 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Acute Ischemic Stroke
Interventions
- Biological: Redasemtide — also filed as Redasemtide trifluoroacetate, S-005151
- Drug: Placebo
Primary outcome
what the primary-completion date above is the date OFModified Rankin Scale (mRS) Score at Day 90
measured Day 90
Permalink · 4507.T's whole pipeline · Catalyst calendar · Every registered study · What changed